Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

FRIMLEY, England, December 8 /PRNewswire/ --

- Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1)

- At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1)

- Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1)

- Novartis Plans to File for Use in Newly Diagnosed Patients With Ph+ CML in the EU in 2010

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.(1)

In the first head-to-head study of these two oral treatments as initial therapy for this life-threatening leukaemia, nilotinib demonstrated statistically significant improvement over imatinib in key measures of effectiveness used in the trial.(1) These new data were presented as a late breaker abstract at the 51st annual meeting of the American Society of Haematology (ASH), held 5-8 December 2009, in New Orleans, USA.(1)

CML accounts for more than one in six leukaemias in adults, with around 600 new cases being registered in England and Wales each year.(2) The estimated prevalence of CML in 2003 in England and Wales was 2,660 patients.(2)

The trial showed that at 12 months, significantly fewer patients on nilotinib 300mg twice-daily progressed from the initial chronic phase of the disease to the later accelerated or blast crisis phases than those on imatinib 400mg once-daily.(1) This demonstrates that nilotinib provided significantly better control of the disease compared to imatinib.

Nilotinib was genera
'/>"/>

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PAUL, Minn. , July 30, 2015 ... medical devices using neuroblocking technology to treat obesity, metabolic ... will host a conference call on Thursday, August 6, ... results for the second quarter ended June 30, 2015, ... the Company,s vBloc® Neurometabolic Therapy, delivered via the Maestro® ...
(Date:7/30/2015)... July 30, 2015 ... reports analyzing tumor biomarker tests, imaging, endoscopy ... for the global industry by technology and ... Industry (Tumor Biomarker Tests, Imaging, Endoscopy and ... talking about 9 companies and supported with ...
(Date:7/29/2015)... Ill. , July 30, 2015  Astellas ... ACTIVE study evaluating the efficacy and safety of ... CRESEMBA® (isavuconazonium sulfate), under development for adults with ... Results from the study demonstrated that the trial ... in overall treatment response in isavuconazole-treated patients at ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... Inc. Magazine has ranked Precision Therapeutics ... growing privately owned companies in the U.S. with a ... This award recognizes the significant accomplishments of the fastest-growing ... established them among the best in their industries.  Precision ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. ... drugstore chain in China based on the number of ... directors has authorized a share repurchase program. Under the ... up to US$20 million worth of its issued and ...
Cached Medicine Technology:Precision Therapeutics Named on Inc. 500|5000 2011 List and Recognized for Achievements in Personalized Medicine Industry 2Precision Therapeutics Named on Inc. 500|5000 2011 List and Recognized for Achievements in Personalized Medicine Industry 3China Nepstar Chain Drugstore Announces Share Repurchase Program 2China Nepstar Chain Drugstore Announces Share Repurchase Program 3
(Date:7/30/2015)... ... July 30, 2015 , ... ... ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill was ... Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard ...
(Date:7/30/2015)... ... , ... Western University of Health Sciences faculty, students and alumni were a ... sports and humanitarian event in the world this year and the single biggest event ... 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of osteopathic ...
(Date:7/30/2015)... ... ... Between 2012 and 2014 HIV infection rates rose from five to seven percent ... untreated heroin use disorders share their needles and spread the infection. Florida does not ... Ultimately Florida’s HIV infection rates have bolstered to 23 percent due to lack of ...
(Date:7/30/2015)... ... 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers ... well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with ... from around the world. , “Like treatment of any other disease or condition, making ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... at Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute ... a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6
... A class of drugs known as the triptans are known ... Since there are seven different triptan drugs available, it is ... at the University of Netherlands have carried out an ... over 18,000 patients. They find that in comparison with the ...
... to a new study, it shows that warfarin and aspirin ... patients at risk. Aspirin prevents blood clotting by stopping platelets ... blood clotting proteins. So both are known to help prevent ... date, it has been thought that warfarin is more effective ...
... the smallpox vaccine is being tested against cervical cancer. ... cervical cancer cases, but not everyone with the virus ... worldwide each year and causes 300,000 deaths. If it ... is a high survival rate. // ,Doctors ...
... sperm is the best indicator of a man's fertility, ... According to Dr. Dav Guzhik, chairman of obstetrics and ... infertility depends upon first establishing what's normal and abnormal. ... semen as normal if it contains 10 million sperm ...
... irregular or very long menstrual cycles have a higher ... needn't panic because the risk can be reduced markedly ... control. // ,Menstrual cycles 40 days or ... some sort of underlying metabolic abnormality. "Over an eight-year ...
... started menstruation could affect whether you suffer allergies.This is due ... development of the child. ,The study of Finnish ... ago. More than 4,740 pregnant women had been asked about ... their children in thirties were given allergy tests against types ...
Cached Medicine News:
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... several (10 to 12) brain slices to ... while maintaining excellent viability. A mixture of ... saline. This initiates a circular flow and ... slices. Slices remain viable for hours while ...
... cooling water for the Vibratome 900R when it is ... in a location which has no source of tap ... thermoelectric heat pump. The reservoir tank holds seven ... 900R for up to eight hours. Water is ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Medicine Products: